Short Interest in Zosano Pharma Co. (NASDAQ:ZSAN) Rises By 40.4%

Zosano Pharma Co. (NASDAQ:ZSANGet Rating) was the target of a large growth in short interest in March. As of March 31st, there was short interest totalling 9,620,000 shares, a growth of 40.4% from the March 15th total of 6,850,000 shares. Based on an average trading volume of 14,750,000 shares, the short-interest ratio is currently 0.7 days.

A number of large investors have recently added to or reduced their stakes in ZSAN. LPL Financial LLC increased its position in Zosano Pharma by 95.7% in the 3rd quarter. LPL Financial LLC now owns 58,700 shares of the biotechnology company’s stock valued at $42,000 after acquiring an additional 28,700 shares during the period. Morgan Stanley boosted its stake in Zosano Pharma by 954.9% during the 1st quarter. Morgan Stanley now owns 45,879 shares of the biotechnology company’s stock valued at $57,000 after purchasing an additional 41,530 shares in the last quarter. Millennium Management LLC bought a new position in Zosano Pharma during the 2nd quarter valued at $65,000. Citadel Advisors LLC boosted its stake in shares of Zosano Pharma by 263.9% during the 3rd quarter. Citadel Advisors LLC now owns 146,166 shares of the biotechnology company’s stock worth $105,000 after acquiring an additional 105,999 shares in the last quarter. Finally, Barclays PLC boosted its stake in shares of Zosano Pharma by 50.0% during the 3rd quarter. Barclays PLC now owns 300,000 shares of the biotechnology company’s stock worth $216,000 after acquiring an additional 100,000 shares in the last quarter. 10.57% of the stock is currently owned by institutional investors.

Zosano Pharma stock opened at $2.93 on Friday. The firm has a market capitalization of $14.18 million, a P/E ratio of -0.31 and a beta of 2.98. The stock has a fifty day moving average price of $8.66 and a 200 day moving average price of $16.03. Zosano Pharma has a 52 week low of $2.90 and a 52 week high of $37.80.

Zosano Pharma (NASDAQ:ZSANGet Rating) last issued its earnings results on Thursday, March 17th. The biotechnology company reported ($2.10) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($2.45) by $0.35. Zosano Pharma had a negative return on equity of 80.12% and a negative net margin of 3,812.10%. The company had revenue of $0.09 million during the quarter. As a group, equities research analysts forecast that Zosano Pharma will post -7.69 EPS for the current fiscal year.

Several research analysts have commented on ZSAN shares. StockNews.com started coverage on Zosano Pharma in a research report on Monday, April 11th. They set a “sell” rating on the stock. BTIG Research lowered Zosano Pharma from a “buy” rating to a “neutral” rating in a report on Wednesday, February 23rd.

About Zosano Pharma (Get Rating)

Zosano Pharma Corp. is a clinical stage biopharmaceutical company, which engages in the development of human pharmaceutical products. The firm focuses on providing rapid systemic administration of therapeutics to patients using proprietary intracutaneous microneedle system. It offers Qtrypta, a formulation of zolmitriptan delivered utilizing the intracutaneous microneedle system.

Featured Articles

Receive News & Ratings for Zosano Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma and related companies with MarketBeat.com's FREE daily email newsletter.